



## *In Utero Fetal Surgery*

<b>Origination:</b> 03/11/09	<b>Revised:</b> 7/23/20	<b>Annual Review:</b> 12/19/23
<b>Line of Business:</b> Commercial Only <input type="checkbox"/> QHP/Exchange Only <input type="checkbox"/> Medicare Only <input type="checkbox"/> Commercial & QHP/Exchange <input type="checkbox"/> Commercial, QHP/Exchange, & Medicare <input checked="" type="checkbox"/>		

### **Purpose:**

To provide in utero fetal surgery guidelines for Population Health and Provider Alliances associates to reference when making determinations.

### ***Additional Information***

- In utero fetal surgery is a relatively new field and covers the application of surgery before birth. A number of congenital abnormalities and fetal disorders have been studied to determine whether they are amenable to fetal intervention. The main objective of fetal surgery is to reverse the underlying pathophysiology during organogenesis in order to ameliorate or prevent the consequences of the associated fetal disorder.

### ***Coverage Guidelines***

- Fetal surgery may be considered medically necessary and covered for the following conditions:
  - 1) Urinary tract obstruction (UTO): Urinary decompression treated via vesicoamniotic shunt placement (VASP) with all of the following conditions:
    - bilateral obstructive uropathy or bilateral hydronephrosis,
    - early onset oligohydramnios/anhydramnios, and
    - severe or progressive but potentially reversible renal damage.
  - 2) Congenital cystic adneomatoid malformation (CCAM) and extralobar pulmonary sequestration (EPS): *Treated with* fetal lobectomy or thoracoamniotic shunt placement for CCAM and thoracoamniotic shunt placement for EPS with all of the following conditions:
    - fetal hydrops,
    - Multicystic lesions, and
    - less than 32 weeks gestation.
  - 3) Sacrococcygeal teratoma (SCT): Treated with resection in cases with massive tumor size, placentomegaly, and fetal hydrops resulting from high-output cardiac failure due to arteriovenous shunting of blood through the tumor.
  - 4) Twin-twin transfusion syndrome (TTTS) and Twin reversed arterial perfusion (TRAP): TTTS treated with fetoscopic laser surgery may be covered at less than 26 weeks of gestation or serial amnioreduction may be covered for TTTS diagnosed at 26 weeks gestation or later. TRAP treated with ablation or occlusion of anastomotic vessels may be covered when all of the following are present:
    - umbilical cord Doppler velocimetry and fetal echocardiography document reverse flow,
    - chromosomal abnormality has been excluded in the pump twin, and
    - ratio of acardiac to pump twin weight is greater than 50%.



## ***In Utero Fetal Surgery***

- Surgery must be performed by physicians and in facilities with demonstrated experience and expertise in fetal surgery.

### ***Exclusion Criteria***

- All other applications of fetal surgery are considered investigational including, but not limited to, the following abnormalities:
  - A. Congenital diaphragmatic hernia (CDH): Treated with fetoscopic temporary tracheal occlusion;
  - B. Congenital Heart Disease (CHD): Including Heart block, Pulmonary valve, or Aortic obstruction;
  - C. Myelomeningocele (MMC) repair;
  - D. Tracheal Atresia / stenosis;
  - E. Cleft lip / Palate.

### **References:**

1. Allen MH, Garabelis NS, Bornick PW, Quintero RA. Minimally invasive treatment of twin-to-twin transfusion syndrome. *AORN J.* 2000 Apr;71(4):796, 801-10; quiz 811-2, 815-8.
2. American College of Obstetricians and Gynecologists (ACOG). Neural tube defects. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2003 Jul. 11 p. (ACOG practice bulletin; no. 44). Accessed October 2008.
3. Berghella V, Kaufmann M. Natural history of twin-twin transfusion syndrome. *J Reprod Med.* 2001 May;46(5):480-4.
4. Biard JM, Johnson MP, Carr MC, et al. Long-term outcomes in children treated by prenatal vesicoamniotic shunting for lower urinary tract obstruction. *Obstet Gynecol.* 2005 Sep;106(3):503-8.
5. Clark TJ, Martin WL, Divakaran TG, et al. Prenatal bladder drainage in the management of fetal lower urinary tract obstruction: a systematic review and meta-analysis. *Obstet Gynecol.* 2003;102(2):367-382.
6. Crombleholme T, Coleman B, Hedrick H, et al. Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. *J Pediatr Surg.* 2002;37(3):331-338.
7. Flake AW, Crombleholme TM, Johnson MP, et al. Treatment of severe congenital diaphragmatic hernia by fetal tracheal occlusion: clinical experience with fifteen cases. *Am J Obstet Gynecol.* 2000;183(5):1059-1066.
8. Flake AW. Surgery in the human fetus: the future. *J Physiol.* 2003;547(1):45-51.
9. Harrison M, Keller R, Hawgood S, et al. A randomized trial of fetal endoscopic tracheal occlusion for severe fetal congenital diaphragmatic hernia. *N Engl J Med.* 2003b;349(20):1916-1924.
10. Hayes, Inc. Hayes Directory. *In Utero Fetal Surgery.* November 2004.



## ***In Utero Fetal Surgery***

11. Hecher K, Lewi L, Gratacos E, Huber A, Ville Y, Deprest J. Twin reversed arterial perfusion: fetoscopic laser coagulation of placental anastomoses or the umbilical cord. *Ultrasound Obstet Gynecol.* 2006 Oct;28(5):688-91.
12. Johnson MP, Gerdes M, Rintoul N, et al. Maternal-fetal surgery for myelomeningocele: neurodevelopmental outcomes at 2 years of age. *Am J Obstet Gynecol.* 2006 Apr;194(4):1145-50; discussion 1150-2.
13. Johnson MP, Sutton LN, Rintoul N, et al. Fetal myelomeningocele repair: short-term clinical outcomes. *Am J Obstet Gynecol.* 2003;189(2):482-487.
14. Kohl T, Sharland G, Allan LD, et al. World experience of percutaneous ultrasound-guided balloon valvuloplasty in human fetuses with severe aortic valve obstruction. *Am J Cardiol.* 2000;85(10):1230-1233.
15. Lee H, Wagner AJ, Sy E, Ball R, Feldstein VA, Goldstein RB, Farmer DL. Efficacy of radiofrequency ablation for twin-reversed arterial perfusion sequence. *Am J Obstet Gynecol.* 2007 May;196(5): 459.e1-4.
16. Tubbs R, Chambers M, Smyth M, et al. Late gestational intrauterine myelomeningocele repair does not improve lower extremity function. *Pediatr Neurosurg.* 2003;38(3):128-132.
17. Tulipan N, Sutton L, Bruner J, et al. The effect of intrauterine myelomeningocele repair on the incidence of shunt-dependent hydrocephalus. *Pediatr Neurosurg.* 2003;38(1):27-33.
18. Tulipan N. Intrauterine closure of myelomeningocele: an update. *Neurosurg Focus.* 2004;16(2):1-4.
19. Tworetzky W, Wilkins-Haug L, et al. Balloon dilation of severe aortic stenosis in the fetus: potential for prevention of hypoplastic left heart syndrome: candidate selection, technique, and results of successful intervention. *Circulation.* 2004 Oct 12;110(15):2125-31.

### **Disclaimer Information:**

Coverage Issues Guidelines and Medical Technology Assessment Recommendations are developed to determine coverage for AvMed's benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. AvMed makes coverage decisions using these guidelines, along with the Member's benefit document. The use of this guideline is neither a guarantee of payment nor a final prediction of how specific claim(s) will be adjudicated.

Coverage Issues Guidelines and Medical Technology Assessment Recommendations are developed for selected therapeutic or diagnostic services found to be safe, but proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in the AvMed service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations.

Treating providers are solely responsible for the medical advice and treatment of Members. This guideline may be updated and therefore is subject to change.